On Friday, we received notice that analysis of the gamma scintigraphy images and plasma pharmacokinetic samples are ongoing from our Phase 1 trial investigating the use of delayed targeted release tablets for colonic delivery of Brilacidin in healthy volunteers. The analysis of gamma scintigraphy images from the study is critical to best evaluate the delivery of Brilacidin directly to the colon. We believe that targeted delivery to the colon is part-and-parcel to the potential future success of Brilacidin as a new oral inflammatory bowel disease drug. We are pleased to inform our shareholders that we expect to release topline results from the trial later this week.
Shareholder Alert: Phase 1 Targeted Delivery Topline Results Expected Later This Week